print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISE.
XIGDUO XR IS NOT RECOMMENDED FOR PATIENTS WITH TYPE 1 DIABETES MELLITUS OR DIABETIC KETOACIDOSIS.

WHAT MORE CAN DO

Approximately 70 g/day at 12 weeks

START WITH ONCE-DAILY XIGDUO XR DUAL-ACTION THERAPY.

GREATER A1C REDUCTION WITH ADDITIONAL WEIGHT* AND SBP BENEFITS1

GREATER A1C REDUCTION WITH ADDITIONAL WEIGHT* AND SBP BENEFITS1

XIGDUO XR is not indicated for weight loss or the treatment of hypertension.

*Up to 7-lb weight reduction was reported in clinical trials.

Vs metformin XR or dapagliflozin.

Approximately 70 g/day at 12 weeks

In a pharmacodynamic study, use of dapagliflozin resulted in excretion of approximately 70 g of glucose in the urine per day at Week 12. Results may vary.

Vs metformin XR or dapagliflozin.